🇺🇸 FDA
Pipeline program

Placebo

NBI-1065845-MDD2024

Phase 2 small_molecule completed

Quick answer

Placebo for Major Depressive Disorder is a Phase 2 program (small_molecule) at NEUROCRINE BIOSCIENCES INC with 1 ClinicalTrials.gov record(s).

Program details

Company
NEUROCRINE BIOSCIENCES INC
Indication
Major Depressive Disorder
Phase
Phase 2
Modality
small_molecule
Status
completed

Clinical trials